Back to News
Market Impact: 0.25
MAIA Doses First U.S. Patient In Phase 2 THIO-101 Trial For Advanced Non-Small Cell Lung Cancer
Source: Nasdaq
Healthcare & Biotech
MAIA Biotechnology dosed the first U.S. patient in its ongoing Phase 2 THIO-101 trial of Ateganosine for third-line non-small cell lung cancer. The milestone advances clinical development of the company’s telomere-targeting lead candidate, but no efficacy or safety data were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
MAIA0.65
More News
- ‘Like Kashmir’: How a toxic marble dump yard became a tourist spot in India
- Swiss firms plan to expand China investments as trade deal deepens ties
- Gaza doctors struggle with bereavement, overwork, trauma amid genocidal war
- OmniAb: A Self-Funding Option Book On 433 Partner Programs
- Regeneron: 3 Key Takeaways for Long-Term Investors
- AbbVie: 3 Key Takeaways for Long-Term Investors